Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy 2026 | MonumenTAL-3 and emerging triplet strategies in multiple myeloma

Meral Beksaç, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses what she is most looking forward to at EHA 2026, highlighting emerging data from the Phase III MonumenTAL-3 study (NCT05455320) evaluating talquetamab in combination with daratumumab, with or without pomalidomide, for relapsed multiple myeloma. She underscores the promising efficacy of this triplet approach and its potential role for patients beyond first relapse. This interview took place at the 12th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So, as usual, EHA and ASCO are one after the other one, and the myeloma abstracts are becoming very dominant in both of the meetings. And this year, I’m one of the authors of the MonumenTAL-3, which is going to be in the plenary session, and we are very happy to see the results, very positive results, and many people have seen the abstract already. And so it’s a new step for, similar to the MajesTEC-3, where the combination of teclistamab with daratumumab produced a fantastic outcome...

So, as usual, EHA and ASCO are one after the other one, and the myeloma abstracts are becoming very dominant in both of the meetings. And this year, I’m one of the authors of the MonumenTAL-3, which is going to be in the plenary session, and we are very happy to see the results, very positive results, and many people have seen the abstract already. And so it’s a new step for, similar to the MajesTEC-3, where the combination of teclistamab with daratumumab produced a fantastic outcome. Now the same success is now being replicated with talquetamab-daratumumab combination with or without pomalidomide. So this is another triplet which is applicable for patients who are relapsing beyond first relapse. So this is one of the presentations that I’m looking forward to.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.